View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 17, 2019

GSK reports positive data from DREAMM-2 multiple myeloma trial

GlaxoSmithKline (GSK) has reported positive results from the open-label DREAMM-2 clinical trial of belantamab mafodotin in patients with multiple myeloma.

GlaxoSmithKline (GSK ) has reported positive results from the open-label DREAMM-2 clinical trial of belantamab mafodotin in patients with multiple myeloma.

Belantamab mafodotin is a humanised immunoconjugate that targets B-cell maturation antigen (BCMA).

DREAMM-2 evaluated 2.5mg/kg and 3.4mg/kg every three weeks in heavily pre-treated patients with actively progressing multiple myeloma even after treatment with the current standard of care.

The trial enrolled patients who had a median of seven previous lines of therapy, were refractory to an immunomodulatory medicine and a proteasome inhibitor, and were refractory and/or intolerant to an anti-CD38 antibody.

Participants experienced a 31% overall response rate (ORR) with the 2.5mg/kg regimen. The company also reported that overall survival in subjects with a response was not reached in the six month follow-up period.

The safety and tolerability profile of the drug was consistent with previous findings. The most common Grade 3 or 4 adverse events relating to the 2.5mg/kg dose were keratopathy, thrombocytopenia and anaemia.

GSK chief scientific officer and R&D president Dr Hal Barron said: “Patients with multiple myeloma whose disease has progressed despite currently available therapy have limited options and poor outcomes.

“Data from the DREAMM-2 study show that, if approved, belantamab mafodotin could offer an important new treatment option for these patients.”

The company submitted a biologics license application to the US Food and Drug Administration (FDA ) for the approval of 2.5mg/kg belantamab mafodotin to treat relapsed or refractory multiple myeloma patients who previously received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

If approved, the drug is expected to be the anti-BCMA agent accessible in the US.

GSK is also studying the drug as third-line monotherapy in relapsed/refractory multiple myeloma, as well as in combination with standard and new therapies in the first and second line setting.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena